8-K
filed January 20, 2023, 6:59 PM ET
ticker SMMT
CIK 0001599298
M&A
confidence high
sentiment neutral
materiality 0.95
Summit closes $500M licensing deal with Akeso for ivonescimab; authorized shares raised to 1B
Summit Therapeutics Inc.
- Upfront payment $500M: $300M paid at close ($274.9M cash + 10M shares valued ~$25.1M); $200M due March 5, 2023.
- Akeso eligible for up to $4.5B milestones plus low double-digit royalties; Summit gets rights in US, Canada, Europe, Japan.
- Dr. Michelle Xia, Akeso CEO, appointed to Summit board.
- Authorized shares increased from 350M to 1B; rights offering up to $500M at discount.
- Summit ceases investments in Discuva platform; continues SMT-738 IND-enabling activities.
Key facts
Extracted from this filing and checked against the source text.
Executive change
SEC 8-K Item 5.02
confidence 0.95
Dr. Yu (Michelle) Xia was appointed as member of the Board of Directors at Summit Therapeutics Inc..
- Action
- appointed
- Role
- member of the Board of Directors
Exact text from the filing
the Board of Directors (the “Board”) of the Company appointed Dr. Yu (Michelle) Xia to serve as a member of the Board pursuant to the terms of the License Agreement.
View on SEC.gov
Governance Changes
SEC 8-K Item 5.03/5.05/5.06
confidence 0.9
Summit Therapeutics Inc.: Increased authorized shares of common stock from 350,000,000 to 1,000,000,000 (effective 2023-01-19).
- Change
- charter amendment
- Effective
- 2023-01-19
Exact text from the filing
On January 19, 2023, Summit filed Amendment No. 2 to the Restated Certificate of Incorporation (the “Amendment No. 2”) with the Secretary of State of the State of Delaware to increase the number of authorized shares of our common stock by 650,000,000 (from 350,000,000 to 1,000,000,000), which became effective on such date.
View on SEC.gov
Material Agreements
SEC 8-K Item 1.01/1.02
confidence 0.9
Summit Therapeutics Inc. entered into Promissory Notes with Robert W. Duggan valued at $400 million and $100 million.
- Action
- entry
- Agreement
- notes offering
- Counterparty
- Robert W. Duggan
- Value
- $400 million and $100 million
Exact text from the filing
Summit and Mr. Duggan have rectified the Original Notes in order to correctly reflect the parties’ intent in the Original Notes
View on SEC.gov
Material Agreements
SEC 8-K Item 1.01/1.02
confidence 0.9
Summit Therapeutics Inc. amended Amendment No. 1 to the License Agreement with Akeso, Inc. (effective 2023-01-16).
- Action
- amendment
- Agreement
- collaboration
- Counterparty
- Akeso, Inc.
- Effective
- 2023-01-16
Exact text from the filing
Common Stock Issuance Agreement As previously disclosed, on December 5, 2022, we entered into a Collaboration and License Agreement (the “License Agreement”) with Akeso, Inc. and its affiliates (“Akeso”) and certain ancillary transaction documents as set forth in the License Agreement.
View on SEC.gov
Material Agreements
SEC 8-K Item 1.01/1.02
confidence 0.9
Summit Therapeutics Inc. entered into Common Stock Issuance Agreement with Akeso (effective 2023-01-17).
- Action
- entry
- Agreement
- equity purchase
- Counterparty
- Akeso
- Effective
- 2023-01-17
Exact text from the filing
Common Stock Issuance Agreement As previously disclosed, on December 5, 2022, we entered into a Collaboration and License Agreement (the “License Agreement”) with Akeso, Inc.
View on SEC.gov
Material Agreements
SEC 8-K Item 1.01/1.02
confidence 0.9
Summit Therapeutics Inc. entered into Collaboration and License Agreement with Akeso, Inc. and its affiliates valued at $500 million upfront payment (effective 2022-12-05).
- Action
- entry
- Agreement
- collaboration
- Counterparty
- Akeso, Inc. and its affiliates
- Value
- $500 million upfront payment
- Effective
- 2022-12-05
Exact text from the filing
on December 5, 2022, we entered into a Collaboration and License Agreement (the “License Agreement”) with Akeso, Inc. and its affiliates
View on SEC.gov
This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice.
See methodology for how this pipeline works.